Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
作者： Hiroshi Noto , Atsushi Goto , Tetsuro Tsujimoto , Mitsuhiko Noda
DOI: 10.1371/JOURNAL.PONE.0033411
关键词:
摘要: Background A growing body of evidence has suggested that metformin potentially reduces the risk cancer. Our objective was to enhance precision estimates effect on any-site and site-specific cancers in patients with diabetes. Methods/principal findings We performed a search MEDLINE, EMBASE, ISI Web Science, Cochrane Library, ClinicalTrials.gov for pertinent articles published as October 12, 2011, included them systematic review meta-analysis. calculated pooled ratios (RRs) overall cancer mortality incidence. Of 21,195 diabetic reported 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases death from were reported. total 11,117 (5.3%) incident at any site among 210,892 10 (2 RCTs, case-control studies). The risks users significantly lower than those non-metformin users: RRs (95% confidence interval) 0.66 (0.49-0.88) mortality, 0.67 (0.53-0.85) all-cancer incidence, 0.68 (0.53-0.88) colorectal (n = 6), 0.20 (0.07-0.59) hepatocellular 4), (0.45-0.99) lung 3). Conclusion/significance use associated However, this analysis is mainly based observational our underscore more need long-term RCTs confirm potential benefit individuals
harvard.edu
paperity.org
core.ac.uk 参考文章(102)
Derek Le Roith, Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. The New England Journal of Medicine. ,vol. 336, pp. 633- 640 ,(1997) , 10.1056/NEJM199702273360907
Berkel H, Yu H, Insulin-like growth factors and cancer. The Journal of the Louisiana State Medical Society. ,vol. 151, pp. 218- ,(1999)
Hiroshi Noto, Tetsuro Tsujimoto, Mitsuhiko Noda, Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians Journal of Diabetes Investigation. ,vol. 3, pp. 24- 33 ,(2012) , 10.1111/J.2040-1124.2011.00183.X
Fei Xue, Karin B Michels, Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence The American Journal of Clinical Nutrition. ,vol. 86, ,(2007) , 10.1093/AJCN/86.3.823S
Tsung-Ming Chen, Chun-Che Lin, Pi-Teh Huang, Chen-Fan Wen, Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation Journal of Gastroenterology and Hepatology. ,vol. 26, pp. 858- 865 ,(2011) , 10.1111/J.1440-1746.2011.06664.X
Valter Donadon, Massimiliano Balbi, Maria Dal Mas, Pietro Casarin, Giorgio Zanette, Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease Liver International. ,vol. 30, pp. 750- 758 ,(2010) , 10.1111/J.1478-3231.2010.02223.X
Bethany B. Barone, Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus JAMA. ,vol. 300, pp. 2754- 2764 ,(2008) , 10.1001/JAMA.2008.824
Yu–Xiao Yang, Sean Hennessy, James D. Lewis, Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. ,vol. 127, pp. 1044- 1050 ,(2004) , 10.1053/J.GASTRO.2004.07.011
T. P. van Staa, D. Patel, A. M. Gallagher, M. L. de Bruin, Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. ,vol. 55, pp. 654- 665 ,(2012) , 10.1007/S00125-011-2390-3
M. F. White, The insulin signalling system and the IRS proteins Diabetologia. ,vol. 40, pp. 2- 17 ,(1997) , 10.1007/S001250051387